Physician profile
Vafa Rekaby
NPI 1104049790
$686.35
in general payments reported to CMS, 2019-2025
17 companies · $36.16 in 2025
The $36.16 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $650 · 2025: $36.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $36.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $36.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $141.31 | 2019 | |
| Novo Nordisk INC | $105.68 | 2019 | |
| Glaxosmithkline, LLC. | $57.17 | 2019 | |
| Merck Sharp & Dohme LLC | $54.18 | 2019 | |
| Pfizer INC. | $48.00 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.55 | 2019 | |
| Genentech USA, INC. | $33.63 | 2019 | |
| Optinose US, INC. | $31.53 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.51 | 2019 | |
| Endo Pharmaceuticals INC. | $31.33 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.09 | 2019 | |
| Amgen INC. | $15.69 | 2019 | |
| Abbvie INC. | $13.92 | 2019 | |
| Lilly USA, LLC | $12.91 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.47 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $12.35 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vafa Rekaby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.